KR930005617A - 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도 - Google Patents

트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도 Download PDF

Info

Publication number
KR930005617A
KR930005617A KR1019920016227A KR920016227A KR930005617A KR 930005617 A KR930005617 A KR 930005617A KR 1019920016227 A KR1019920016227 A KR 1019920016227A KR 920016227 A KR920016227 A KR 920016227A KR 930005617 A KR930005617 A KR 930005617A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
trimadol
oxycodone
codeine
component
Prior art date
Application number
KR1019920016227A
Other languages
English (en)
Other versions
KR100236666B1 (ko
Inventor
비. 라파 로버트
엘. 바우트 제프리
Original Assignee
스티븐 피. 버만
맥네리랩 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 피. 버만, 맥네리랩 인코포레이티드 filed Critical 스티븐 피. 버만
Publication of KR930005617A publication Critical patent/KR930005617A/ko
Application granted granted Critical
Publication of KR100236666B1 publication Critical patent/KR100236666B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

본 발명은 트라마돌 성분과 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도에 관한 것이다. 본 발명의 조성물은 통증, 설사 및 해소상태의 치료에 약물적으로 유용하다. 이 조성물은 또한 순수한 아편-기본 조성물에 비해 남용성, 내성, 변비 및 호흡억제와 같은 부작용을 덜 나타낸다. 또한, 본 발명 조성물의 성분들, 즉 트라마돌 성분과 코데인, 옥시코돈 또는 하이드로코돈을 특정비로 사용하면 조성물의 약물학적 효과는 상승적으로 나타난다.

Description

트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 마우스에서 고리-튕김 잠복기간(tail-flick latency)에 대한 트라마돌 하이드로클로라이드와 코데인 포스페이트 조성물의 진통효과를 나타내는 이소볼로그램(isobologram)이다,
제2도는 마우스에서 꼬리-튕김 잠복기간에 대한 트리마돌 하이드로클로라이드와 옥시코돈 하이드로클로라이드 조성물의 진통 효과를 나타내는 이소볼로그램이다.

Claims (16)

  1. 트리마돌 성분, 및 코데인, 옥시코돈 및 하이드로코돈으로 구성된 그룹중에서 선택된 아편양 제제를 함유하는 약제학적 조성물.
  2. 제1항에 있어서, 트리마돌 성분과 아편양 제제를 상승적 약리효과가 제공되기에 충분한 비율로 함유하는 약제학적 조성물.
  3. 제2항에 있어서, 아편양 제제가 코데인인 약제학적 조성물.
  4. 제3항에 있어서, 트리마돌 성분이 트리마돌 하이드로클로라이드인 약제학적 조성물.
  5. 제4항에 있어서, 트리마돌 하이드로클로라이드가 라세미체인 약제학적 조성물.
  6. 제5항에 있어서, 트리마돌 성분과 아편양 제제가 약 1:20 내지 약 20:1의 중량비로 함유된 약제학적 조성물.
  7. 제6항에 있어서, 중량비가 약 1:2 내지 약 2:1인 약제학적 조성물.
  8. 제7항에 있어서, 중량비가 약 1:1 내지 약 2:1인 약제학적 조성물.
  9. 제2항에 있어서, 아편양 제제가 옥시코돈인 약제학적 조성물.
  10. 제9항에 있어서, 트리마돌 성분이 트리마돌 하이드로클로라이드인 약제학적 조성물.
  11. 제10항에 있어서, 트리마돌 하이드로클로라이드가 라세미체인 약제학적 조성물.
  12. 제11항에 있어서, 트리마돌 성분과 약 200:1 내지 약 1:1의 중량비로 함유된 약제학적 조성물.
  13. 제12항에 있어서, 중량비가 약 20:1 내지 약 1:1인 약제학적 조성물.
  14. 제1항에 있어서, 추가로 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  15. 포유동물에게 제1항의 약제학적 조성물을 투여함을 특징으로 하여 포유동물의 약리적 상태를 치료하는 방법.
  16. 제15항에 있어서, 약리적 상태가 통증인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920016227A 1991-09-06 1992-09-05 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도 KR100236666B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75592391A 1991-09-06 1991-09-06
US755,923 1991-09-06

Publications (2)

Publication Number Publication Date
KR930005617A true KR930005617A (ko) 1993-04-20
KR100236666B1 KR100236666B1 (ko) 2000-03-02

Family

ID=25041253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920016227A KR100236666B1 (ko) 1991-09-06 1992-09-05 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도

Country Status (22)

Country Link
US (1) US5468744A (ko)
EP (1) EP0534628B1 (ko)
JP (1) JP3244540B2 (ko)
KR (1) KR100236666B1 (ko)
CN (1) CN1051705C (ko)
AT (1) ATE145330T1 (ko)
AU (1) AU657351B2 (ko)
CA (1) CA2077637C (ko)
DE (1) DE69215316T2 (ko)
DK (1) DK0534628T3 (ko)
ES (1) ES2096726T3 (ko)
GR (1) GR3022515T3 (ko)
HU (1) HU217584B (ko)
IL (1) IL103070A (ko)
MX (1) MX9205106A (ko)
MY (1) MY110317A (ko)
NO (1) NO300197B1 (ko)
NZ (1) NZ244250A (ko)
PH (1) PH31112A (ko)
TW (1) TW271394B (ko)
ZA (1) ZA926732B (ko)
ZW (1) ZW14392A1 (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651247B2 (en) 1991-09-06 1994-07-14 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
GB9523566D0 (en) * 1995-11-17 1996-01-17 Euro Celtique Sa Pharmaceutical formulation
DE19601744C2 (de) 1996-01-19 1998-04-16 Gruenenthal Gmbh Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
DE19641576C1 (de) * 1996-10-09 1998-05-07 Gruenenthal Gmbh Kombinationspräparat enthaltend Tramadol und einen Calcium-Kanal Antagonisten
DE19712398A1 (de) * 1997-03-25 1998-10-01 Gruenenthal Gmbh Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
DK0996613T3 (da) 1997-07-15 2003-03-03 Russinsky Ltd Fremstilling af rent cis-tramadol-hydrochlorid
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
HUP0203198A3 (en) 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
PE20010623A1 (es) 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001034125A2 (en) * 1999-11-09 2001-05-17 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
CA2506807A1 (en) * 2002-12-13 2004-07-01 Cilag Ag Controlled release preparations comprising tramadol and topiramate
EP2004190A4 (en) * 2006-03-15 2011-02-16 Biotech Pharmaceuticals Pty Ltd NON-CODEIN OPIOID ANALGETIC PROCESS AND FORMULATIONS
PT2596784T (pt) * 2007-11-23 2017-03-29 Gruenenthal Gmbh Composições de tapentadol
US20090264454A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined hydrocodone and analgesic formulation and method
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
WO1993002707A1 (de) * 1991-08-06 1993-02-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue antidiarrhoica
AU2062892A (en) * 1991-08-16 1993-02-18 Mcneil-Ppc, Inc. Potentiation of antitussive effect of dextromethorphan

Also Published As

Publication number Publication date
MX9205106A (es) 1993-05-01
IL103070A0 (en) 1993-02-21
ATE145330T1 (de) 1996-12-15
EP0534628B1 (en) 1996-11-20
MY110317A (en) 1998-04-30
CA2077637C (en) 2007-01-09
ZA926732B (en) 1994-03-04
EP0534628A1 (en) 1993-03-31
IL103070A (en) 1996-10-16
DK0534628T3 (da) 1996-12-09
AU2218592A (en) 1993-03-11
US5468744A (en) 1995-11-21
ES2096726T3 (es) 1997-03-16
HU217584B (hu) 2000-02-28
JP3244540B2 (ja) 2002-01-07
NO300197B1 (no) 1997-04-28
JPH06107540A (ja) 1994-04-19
CN1051705C (zh) 2000-04-26
TW271394B (ko) 1996-03-01
NO923453L (no) 1993-03-08
DE69215316D1 (de) 1997-01-02
GR3022515T3 (en) 1997-05-31
AU657351B2 (en) 1995-03-09
PH31112A (en) 1998-02-23
NZ244250A (en) 1994-01-26
HUT63556A (en) 1993-09-28
DE69215316T2 (de) 1997-03-20
HU9202845D0 (en) 1992-11-30
KR100236666B1 (ko) 2000-03-02
NO923453D0 (no) 1992-09-04
CA2077637A1 (en) 1993-03-07
CN1071835A (zh) 1993-05-12
ZW14392A1 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
KR930005617A (ko) 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도
Smith et al. The interaction of ketamine with the opiate receptor
ES2120451T3 (es) Composicion que contiene un compuesto de la familia del tramadol y del acetaminofeno, y su utilizacion.
Harris et al. Narcotic-antagonist analgesics: interactions with cholinergic systems
US3773955A (en) Analgetic compositions
TW329386B (en) Cough medicine
MX9206257A (es) Composicion que comprende material de tramadol y un farmaco anti-inflamatorio no esteroidal.
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
Funada et al. A new opioid analgesic KT90: Analgesia and dependence liability
KR950702830A (ko) 치환된 아자스피란을 사용한 건선 치료 방법(methods of treating psoriasis employing substituted azaspiranes)
KR920702623A (ko) 진해제
Coalson et al. Effects of Different Doses of Naloxone on the Subjective and Psychomotor Effects of Nitrous Oxide in Humans
Acri et al. Effects of dopamine uptake inhibitors on behavioral and toxic effects of cocaine
Acri et al. Characterization of the Discriminative Stimulus Effects of Benztropine, A Potential Cocaine Therapeutic Agent
MY114755A (en) Composition comprising a tramadol material and acetaminophen and its use.
Endoh et al. Two Different Antagonisms of Nor-BNI Against Morphine on Intestinal Transit in Mice
Rosow Agonist-Antagonists and their Receptors
Adams et al. Receptor selectivity of the analgesic effects of icv morphine in the cold water tail-flick test in rats
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
JPS57128626A (en) Analgesic composition
Reid et al. Evidence that Ibogaine Modulates Dopamine Release via a Kappa Receptor Mechanism
Marley et al. Enhanced Sensitivity to Naltrexone is Associated with Changes in the Number of Mu and Delta Opioid Receptors in Rat Brain
KR920002150A (ko) 항말라리아 약학적 배합제
KR880007075A (ko) 안크시올리틱-n-(1-아자비시클로[2.2.2]옥트-3-일)벤즈아미드와 티오벤즈아미드

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110919

Year of fee payment: 13

EXPY Expiration of term